Prasugrel (Maleic acid)  (Synonyms: 马来酸普拉格雷; PCR 4099 (Maleic acid))

Prasugrel (PCR 4099) Maleic acid is a thienopyridine and proagent, inhibits platelet function. Prasugrel Maleic acid is an orally active and potent P2Y12 receptor antagonist, and inhibits ADP-induced platelet aggregation^[1].

In rat platelets, Prasugrel (PCR 4099) Maleic acid active metabolite inhibits in vitro platelet aggregation induced by adenosine ADP (10μM) with an IC₅₀ value of 1.8 μM^[2].
Prasugrel (PCR 4099) Maleic acid acts faster and is significantly more potent than Clopidogrel in vivo. Prasugrel hydrochloride is an inactive prodrug that requires metabolic processing in vivo to generate the active antiplatelet metabolite. Prasugrel (PCR 4099) Maleic acid is rapidly absorbed from the gut. After oral administration of standard-loading doses of 60 mg, maximum plasma levels of the active metabolite are achieved within 1 h, effective, maximum inhibition of platelet aggregation at 1-2 h^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

489.51

C₂₄H₂₄FNO₇S

389574-20-3

马来酸普拉格雷

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Wijeyeratne YD, et al. Anti-platelet therapy: ADP receptor antagonists. Br J Clin Pharmacol. 2011 Oct;72(4):647-57.  [Content Brief]

  [2]. Sugidachi A, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite. J Thromb Haemost. 2007 Jul;5(7):1545-51.  [Content Brief]